Biomaxima Total Liabilities
Biomaxima total liabilities. Based on the latest financial reports, Biomaxima (BMX) has total liabilities worth zł30.50 Million PLN (≈ $8.39 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Biomaxima's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biomaxima (2009–2024)
Total liabilities of Biomaxima from 2009 to 2024. This chart illustrates how Biomaxima's total liabilities have evolved over time, based on quarterly financial data. Explore BMX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Biomaxima Competitors by Total Liabilities
The table below lists competitors of Biomaxima ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wetouch Technology Inc. Common Stock
NASDAQ:WETH
|
USA | $4.12 Million |
|
General Engineering Public Company Limited
BK:GEL
|
Thailand | ฿5.51 Billion |
|
Nagambie Resources Ltd
AU:NAG
|
Australia | AU$10.28 Million |
|
Seamless Distribution Systems AB
ST:SDS
|
Sweden | Skr339.60 Million |
|
Agillic A/S
CO:AGILC
|
Denmark | Dkr65.59 Million |
|
OYAK Yatirim Ortakligi AS
IS:OYAYO
|
Turkey | TL2.89 Million |
|
MODERN COMMERCE SA ZY-10
F:8F4
|
Germany | €19.97 Million |
|
Esthetics International Group
KLSE:5081
|
Malaysia | RM103.77 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Biomaxima's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BMX total asset value.
Liquidity & Leverage Metrics
Biomaxima Total Liabilities Ratios Explained
Biomaxima total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomaxima's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomaxima (2009–2024)
The table below shows the annual total liabilities of Biomaxima from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł29.01 Million ≈ $7.98 Million |
+8.21% |
| 2023-12-31 | zł26.81 Million ≈ $7.38 Million |
+22.05% |
| 2022-12-31 | zł21.96 Million ≈ $6.05 Million |
-32.90% |
| 2021-12-31 | zł32.74 Million ≈ $9.01 Million |
+19.08% |
| 2020-12-31 | zł27.49 Million ≈ $7.57 Million |
+2.42% |
| 2019-12-31 | zł26.84 Million ≈ $7.39 Million |
-1.01% |
| 2018-12-31 | zł27.11 Million ≈ $7.46 Million |
+173.06% |
| 2017-12-31 | zł9.93 Million ≈ $2.73 Million |
+50.85% |
| 2016-12-31 | zł6.58 Million ≈ $1.81 Million |
+4.07% |
| 2015-12-31 | zł6.33 Million ≈ $1.74 Million |
-8.73% |
| 2014-12-31 | zł6.93 Million ≈ $1.91 Million |
-15.73% |
| 2013-12-31 | zł8.22 Million ≈ $2.26 Million |
+24.03% |
| 2012-12-31 | zł6.63 Million ≈ $1.82 Million |
+25.67% |
| 2011-12-31 | zł5.28 Million ≈ $1.45 Million |
+39.96% |
| 2010-12-31 | zł3.77 Million ≈ $1.04 Million |
+48.18% |
| 2009-12-31 | zł2.54 Million ≈ $700.15K |
-- |
About Biomaxima
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid… Read more